



EFW

PTO/SB/21 (02-04)

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	10/719,692
Filing Date	November 21, 2003
First Named Inventor	An, Songzhu
Art Unit	1645
Examiner Name	Not yet assigned
Attorney Docket Number	018781-009530US

Total Number of Pages in This Submission 5

ENCLOSURES (Check all that apply)

- | | | |
|---|---|---|
| <input type="checkbox"/> Fee Transmittal Form
<input type="checkbox"/> Fee Attached
<input type="checkbox"/> Amendment/Reply
<input type="checkbox"/> After Final
<input type="checkbox"/> Affidavits/declaration(s)
<input type="checkbox"/> Extension of Time Request
<input type="checkbox"/> Express Abandonment Request
<input checked="" type="checkbox"/> Information Disclosure Statement
<input type="checkbox"/> Certified Copy of Priority Document(s)
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application

<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Drawing(s)
<input type="checkbox"/> Licensing-related Papers
<input type="checkbox"/> Petition
<input type="checkbox"/> Petition to Convert to a Provisional Application
<input type="checkbox"/> Power of Attorney, Revocation
Change of Correspondence Address
<input type="checkbox"/> Terminal Disclaimer
<input type="checkbox"/> Request for Refund
<input type="checkbox"/> CD, Number of CD(s) _____ | <input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Status Letter
<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): <ul style="list-style-type: none">• Return Postcard• Copies of cited references A1-A50 |
|---|---|---|

Remarks The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Townsend and Townsend and Crew LLP
Signature	Jean M. Lockyer, Ph.D.
Date	June 24, 2004

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Marina A. Lewis		
Signature		Date	June 24, 2004

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Date: June 24, 2004

TOWNSEND and TOWNSEND and CREW LLP

By: 

Marina A. Lewis

PATENT
Attorney Docket No.: 018781-009530US
Client Reference No.: T02-011-2/US



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

AN et al.

Application No.: 10/719,692

Filed: November 21, 2003

For: RECEPTOR LIGANDS AND
METHODS OF MODULATING
RECEPTORS

Examiner: Not yet assigned

Art Unit: 1645

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.97 and §1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. In accordance with the USPTO waiver of the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. patent applications filed after June 30, 2003, applicant has not submitted copies of references A1-A3. Copies of all non-U.S. patent and literary references are enclosed. It is respectfully requested that the cited references be expressly

considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.


As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement.

However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Date: June 24, 2004


Respectfully submitted,

A handwritten signature in black ink, appearing to read "Jean M. Lockyer", is written over the typed name and registration number.

Jean M. Lockyer, Ph.D.
Reg. No. 44,879

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300

JML:mal



Substitute for form PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known	
			Application Number	10/719,692
			Filing Date	November 21, 2003
			First Named Inventor	An, Songzhu
			Art Unit	1645
			Examiner Name	Not yet assigned
Sheet 1 of 3	Attorney Docket Number	018781-009530US		

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	US-6,500,938 B1	12-31-2002	Au-Young, et al.	
	A2	US-6,555,339 B1	04-29-2003	Liaw, et al.	
	A3	US-2002-0052022 A1	05-02-2002	Elshourbagy, et al.	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	A4	EP	1270724	A2	01-02-2003	1) National Institute of Advanced Industrial Science and Technology; and 2) Center for Advanced Science and Technology Incubation, Ltd.		N/A
	A5	WO	98/56820	A1	12-17-1998	Smithkline Beecham Corporation		N/A
	A6	WO	00/22129	A1	04-20-2000	Arena Pharmaceuticals, Inc.		N/A
	A7	WO	01/36471	A2	05-25-2001	Arena Pharmaceuticals, Inc.		N/A
	A8	WO	01/36473	A2	05-25-2001	Pharmacia & Upjohn Company		N/A
	A9	WO	01/73029	A2	10-04-2001	PE Corporation		N/A
	A10	WO	01/74904	A2	10-11-2001	Curagen Corporation		N/A
	A11	WO	01/77320	A2	10-18-2001	Bayer AG		N/A
	A12	WO	01/77326	A1	10-18-2001	Takeda Chemical Industries, Ltd.		<input type="checkbox"/>
	A13	WO	01/87937	A2	11-22-2001	Incyte Genomics, Inc.		N/A
	A14	WO	01/94385	A2	12-13-2001	Bayer AG		N/A
	A15	WO	01/94629	A2	12-13-2001	Avalon Pharmaceuticals		N/A
	A16	WO	01/98330	A2	12-27-2001	Euroscreen S.A.		N/A
	A17	WO	02/02767	A1	01-10-2002	Takeda Chemical Industries, Ltd.		<input type="checkbox"/>
	A18	WO	02/06466	A1	01-24-2002	Takeda Chemical Industries, Ltd.		<input type="checkbox"/>
	A19	WO	02/13845	A2	02-21-2002	Novartis AG		N/A
	A20	WO	02/18579	A2	03-07-2002	Millennium Pharmaceuticals, Inc.		N/A
	A21	WO	02/18938	A1	03-07-2002	Boehringer Ingelheim Pharma KG		N/A
	A22	WO	02/28999	A2	04-11-2002	Gene Logic, Inc.		N/A
	A23	WO	02/061087	A2	08-08-2002	Lifespan Biosciences, Inc.		N/A
	A24	WO	02/072755	A2	09-19-2002	Bristol-Myers Squibb Company		N/A
	A25	WO	02/084298	A2	10-24-2002	Glaxo Group Limited		N/A
	A26	WO	03/021262	A1	03-13-2003	Takeda Chemical Industries, Ltd.		<input type="checkbox"/>

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/719,692	
			Filing Date	November 21, 2003	
			First Named Inventor	An, Songzhu	
			Art Unit	1645	
			Examiner Name	Not yet assigned	
Sheet	2	of	3	Attorney Docket Number	018781-009530US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A27	AKTORIES, K., et al., "Nicotinic Acid Inhibits Adipocyte Adenylate Cyclase in a Hormone-Like Manner", <i>Elsevier/North-Holland Biomedical Press</i> (June 1980), Vol. 115, No. 1, pp. 11-14.	
	A28	BALDWIN, G., et al., "Gut Hormones, Growth and Malignancy", <i>Baillière's Clinical Endocrinology and Metabolism</i> (January 1994), Vol. 8, No. 1, pp. 185-214)	
	A29	BERRIDGE, M., et al., "Inositol Trisphosphate, a Novel Second Messenger in Cellular Signal Transduction", <i>Nature</i> (November 22, 1984), Vol. 312, pp. 315-321.	
	A30	BROWN, M., et al., <u>Drugs Used in the Treatment of Hyperlipoproteinemias</u> , Goodman and Gillman (1990) 8 th Ed., Ch. 36, pp. 889-891.	
	A31	BROWN, W., et al., "Nicotinic Acid and its Derivatives", Medical Research Foundation, Washington, D.C., pp. 189-213.	
	A32	BUCK, L., et al., "A Novel Multigene Family May Encode Odorant Receptors: A Molecular Basis for Odor Recognition", <i>Cell</i> , (April 5, 1991), Vol. 65, pp. 175-187.	
	A33	DIPALMA, J., et al., "Use of Niacin as a Drug", <i>Annual Review of Nutrition</i> (1991), Vol. 11, pp. 169-187.	
	A34	FELLEY-BOSCO, E., et al., "Constitutive Expression of Inducible Nitric Oxide Synthase in Human Bronchial Epithelial Cells Induces c-fos and Stimulates the cGMP Pathway", <i>American Journal of Respiratory Cell and Molecular Biology</i> (1994), Vol. 11, pp. 159-164.	
	A35	FONG, T., "Mechanistic Hypotheses for the Activation of G-Protein-Coupled Receptors", <i>Cell Signal</i> (1996), Vol. 8, No. 3, pp. 217-224.	
	A36	GEY, K., et al., eds., <u>Metabolic Effects of Nicotinic Acid and its Derivatives</u> , Proceedings from Workshop on the Metabolic Effects of Nicotinic Acid and its Derivatives, Flims, Switzerland, March 23-25, 1970, (Publisher, Hans Huber, Bern, Switzerland, 1971).	
	A37	KAIJSER, L., et al., "Dissociation of the Effects of Nicotinic Acid on Vasodilatation and Lipolysis by a Prostaglandin Synthesis Inhibitor, Indomethacin, in Man", <i>Medical Biology</i> (1979), Vo. 57, pp. 114-117.	
	A38	LANES, R., et al., "Acipimox, a Nicotinic Acid Analog, Stimulates Growth Hormone Secretion in Short Healthy Prepubertal Children", <i>Journal of Pediatric Endocrinology & Metabolism</i> (2000), Vol. 13, pp. 1115-1120.	
	A39	LEE, D., et al., "Discovery and Mapping of Ten Novel G Protein-Coupled Receptor Genes", <i>Gene</i> (2001), Vol. 275, pp. 83-91.	
	A40	LORENZEN, A., et al., "Characterization of a G Protein-Coupled Receptor for Nicotinic Acid", <i>Molecular Pharmacology</i> (2001), Vol. 59, pp. 349-357.	
	A41	LORENZEN, A., et al., "G Protein-Coupled Receptor for Nicotinic Acid in Mouse Macrophages", <i>Biochemical Pharmacology</i> (2002), Vol. 64, pp. 645-648.	
	A42	MCINTOSH, C., et al., "Glucose-Dependent Insulinotropic Polypeptide Stimulation of Lipolysis in Differentiated 3T3-L1 Cells: Wortmannin-Sensitive Inhibition by Insulin", <i>Endocrinology</i> (1999), Vol. 140, No. 1, pp. 398-404.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/719,692
				Filing Date	November 21, 2003
				First Named Inventor	An, Songzhu
				Art Unit	1645
				Examiner Name	Not yet assigned
Sheet	3	of	3	Attorney Docket Number	018781-009530US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A43	MIYAI, K., et al., "Synthesis and Antiinflammatory Activity of 6-Oxo-1-(β-D-ribofuranosyl)nicotinic Acid and Related Derivatives", <i>Journal of Medicinal Chemistry</i> (1978), Vol. 21, No. 5, pp. 427-430.	
	A44	MONZON, J., "Lipolysis in Adipocytes Isolated from Deep and Superficial Subcutaneous Adipose Tissue", <i>Obesity Research</i> (April 2002), Vol. 10, No. 4, pp. 266-269.	
	A45	MORRIS, A., et al., "Physiological Regulation of G Protein-Linked Signaling", <i>Physiological Reviews</i> (October 1999), Vol. 79, No. 4, pp. 1373-1430.	
	A46	NOMURA, H., et al., "Molecular Cloning of cDNAs Encoding a LD78 Receptor and Putative Leukocyte Chemotactic Peptide Receptors", <i>International Immunology</i> (1993), Vol. 5, No. 10, pp. 1239-1249.	
	A47	OFFERMANN, S., et al., "G _{α15} and G _{α16} Couple a Wide Variety of Receptors to Phospholipase C", <i>The Journal of Biological Chemistry</i> (June 23, 1995), Vol. 270, No. 25, pp. 15175-15180.	
	A48	SCHAUB, A., et al., "PUMA-G, and IFN-γ-inducible Gene in Macrophages is a Novel Member of the Seven Transmembrane Spanning Receptor Superfamily", <i>European Journal of Immunology</i> (2001), Vol. 31, pp. 3714-3725.	
	A49	STABLES, J., et al., "A Bioluminescent Assay for Agonist Activity at Potentially Any G-Protein-Coupled Receptor", <i>Analytical Biochemistry</i> (1997), Vol. 252, pp. 115-126.	
	A50	WILKIE, T., et al., "Characterization of G-protein α subunits in the G _q Class: Expression in Murine Tissues and in Stromal and Hematopoietic Cell Lines", <i>Proceedings of the National Academy of Sciences of the United States of America</i> (November 1991), Vol. 88., pp. 10049-10053.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.